Anti-Asthma TDM Assay Kits Market size is poised to cross USD 32 Billion by the end of 2035, growing at a CAGR of 6% during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of anti-asthma TDM assay kits was over USD 18 Billion. The growth of the market can be attributed to the escalating cases of asthma worldwide. TDM is used to measure the plasma concentration of the drug in the given therapy, and it involves measuring drug concentration and clinical interpretation of the result. Asthma is thought to affect at least 300 million individuals worldwide, 30 million of whom reside in mainland China.
In addition to these, factors that are believed to fuel the market growth of anti-asthma TDM assay kits include the rise in the consumption of tobacco. Scientists claim that tobacco smoke is a common trigger for asthma. The smoke from tobacco products, such as cigars, cigarettes, or pipes can aggravate the condition. The data released by the World Health Organization states that in 2020, 22.3% of the world population used tobacco. On account of excessively increasing tobacco users, the global anti-asthma TDM assay kits market is estimated to grow during the forecast period. Also, the worsening air quality is causing various respiratory diseases and asthma is the most common of all. This is also estimated to fuel the global anti-asthma TDM assay kits market growth during the forecast period. The World Health Organization (WHO) estimates that, as of 2019, 99% of the world's population resided in areas where the WHO's air quality standards were not being met. According to data from the same year, more than 90% of individuals worldwide lived in regions where PM2.5 concentrations were higher than the WHO annual air quality criteria (AQG), which are 10 g/m3.
Growth Drivers
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
6% |
|
Base Year Market Size (2022) |
USD 18 Billion |
|
Forecast Year Market Size (2035) |
USD 32 Billion |
|
Regional Scope |
|
The global anti-asthma TDM assay kits market is segmented and analyzed for demand and supply by product type into ELISA assay kits, immunoassay kits, and others. Out of the three types of products, the ELISA assay kits segment is estimated to gain the largest market share over the projected time frame. The enzyme-linked immunosorbent assay, or ELISA test, quantifies the quantity of allergen-specific antibodies in our body. The growth of the segment can be attributed to the rise in the number of variants of ELISA test kits manufactured in the market. For instance, a leading manufacturer of China, Wuhan Fine Biotech Co., Ltd. currently have more than 7600 types of ELISA kits in the market.
The global anti-asthma TDM assay kits market is also segmented and analyzed for demand and supply by end-user in hospitals, diagnostic laboratories, research centers & academic institutes. Amongst these three segments, the hospital segment is expected to garner a significant share. Patients suffering from asthma often visit hospitals for treatment, and Acute asthma attacks continue to be a common reason for ER visits and hospital admissions. In 2018, around 6 million asthma patients visited hospitals for treatment. Moreover, in the same year, around 180,000 people were discharged from hospital inpatient care and nearly 2 million asthmatic patients were released from the hospital's emergency department. Furthermore, asthma-related visits to the emergency room are approximately five times as common among black Americans than among white Americans.
Our in-depth analysis of the global anti-asthma TDM assay kits market includes the following segments:
|
By Product Type |
|
|
By Assay Type |
|
|
By End User |
|
North America Market Forecast
The North American anti-asthma TDM assay kits market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The growth of the market can be attributed majorly to the increasing count of patients suffering from asthma. A recent report published by the Asthma and Allergy Foundation of America states that approximately 25 million people living in the United States have asthma. On the other hand, the deteriorating quality of air in the region is expected to boost the market growth in the region. Research by the American Lung Association found that more than 135 million Americans breathe toxic air, putting their health and lives in danger.
Thermo Fisher Scientific joins hands with TransMIT GmbH on an Orbitrap Mass Spectrometry Imaging Platform.
Carterra and Bio-Techne, a leading supplier of innovative and high-quality tools for life science research, collaborated on clinical research for the COVID-19 variant analysis.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?